Dr. Orban is an Associate Investigator in the Section on Immunobiology at Joslin Diabetes Center, Boston, and an Instructor in Medicine at Harvard Medical School. Dr. Orban is one of the Principal Investigators in three major networks—TrialNet, Immune Tolerance Network (ITN) and Autoimmune Center of Excellence (ACE). Dr. Orban is engaged in development of antigen-specific immunotherapy to stop the immune system from attacking the body’s own insulin-producing beta cells by re-establishing self-tolerance and has completed a Phase 1 clinical study sponsored by ITN/NIH.
Dr. Lemere is currently Associate Professor of Neurology, Harvard Medical School and a Scientist at the Center for Neurologic Diseases at Brigham and Women’s Hospital. The main focus of Dr. Lemere’s research is to find a way to prevent or treat Alzheimer’s disease and she has made significant contributions to vaccine approaches against beta-amyloid protein. Dr Lemere has led studies to evaluate the mechanism of action of MER5101 for prevention and treatment of Alzheimer’s Disease in both naïve and transgenic animal models of this disease.
Dr. Grunig is currently Associate Professor, Environmental Medicine, NYU School of Medicine, NY. Dr. Grunig’s research focuses on aspects of pulmonary hypertension that are associated with autoimmune diseases, chronic inflammatory conditions and parasitic infections. With Mercia, Dr. Grunig is investigating how the simultaneous targeting of multiple chemical messengers (cytokines and chemokines) may reduce chronic pulmonary inflammation associated with asthma and allergic diseases and chronic obstructive pulmonary disease (COPD), work funded in part by a grant to Mercia, NIH 1 R41 A1074114.
Dr. Treanor is currently Chief, Dept of Medicine, University of Rochester, NY, and Professor in the departments of Medicine, Microbiology and Immunology, and the Center for Vaccine Biology and Immunology. Dr. Treanor is a widely recognized expert in influenza and vaccine research. Dr Treanor’s laboratory has contributed to the immunopharmacological evaluation of MER4101, Mercia’s MAS-1 adjuvanted influenza vaccine, work funded in part by a grant to Mercia, NIH 1 R43 A1074119